Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Aug 1, 1996; 98(3): 741–749.
PMCID: PMC507484

Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs.


Suppression of hepatic glucose output (HGO) has been shown to be primarily mediated by peripheral rather than portal insulin concentrations; however, the mechanism by which peripheral insulin suppresses HGO has not yet been determined. Previous findings by our group indicated a strong correlation between free fatty acids (FFA) and HGO, suggesting that insulin suppression of HGO is mediated via suppression of lipolysis. To directly test the hypothesis that insulin suppression of HGO is causally linked to the suppression of adipose tissue lipolysis, we performed euglycemic-hyperinsulinemic glucose clamps in conscious dogs (n = 8) in which FFA were either allowed to fall or were prevented from falling with Liposyn plus heparin infusion (LI; 0.5 ml/min 20% Liposyn plus 25 U/min heparin with a 250 U prime). Endogenous insulin and glucagon were suppressed with somatostatin (1 microgram/min/kg), and insulin was infused at a rate of either 0.125 or 0.5 mU/min/kg. Two additional experiments were performed at the 0.5 mU/min/kg insulin dose: a double Liposyn infusion (2 x LI; 1.0 ml/min 20% Liposyn, heparin as above), and a glycerol infusion (19 mg/min). With the 0.125 mU/min/kg insulin infusion, FFA fell 40% and HGO fell 33%; preventing the fall in FFA with LI entirely prevented this decline in HGO. With 0.5 mU/min/kg insulin infusion, FFA levels fell 64% while HGO declined 62%. Preventing the fall in FFA at this higher insulin dose largely prevented the fall in HGO; however, steady state HGO still declined by 18%. Doubling the LI infusion did not further affect HGO, suggesting that the effect of FFA on HGO is saturable. Elevating plasma glycerol levels did not alter insulin's ability to suppress HGO. These data directly support the concept that insulin suppression of HGO is not direct, but rather is mediated via insulin suppression of adipose tissue lipolysis. Thus, resistance to insulin control of hepatic glucose production in obesity and/or non-insulin-dependent diabetes mellitus may reflect resistance of the adipocyte to insulin suppression of lipolysis.

Full Text

The Full Text of this article is available as a PDF (218K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Rebrin K, Steil GM, Getty L, Bergman RN. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes. 1995 Sep;44(9):1038–1045. [PubMed]
  • Ader M, Bergman RN. Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am J Physiol. 1990 Jun;258(6 Pt 1):E1020–E1032. [PubMed]
  • Giacca A, Fisher SJ, Shi ZQ, Gupta R, Lickley HL, Vranic M. Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. J Clin Invest. 1992 Nov;90(5):1769–1777. [PMC free article] [PubMed]
  • Prager R, Wallace P, Olefsky JM. Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes. 1987 May;36(5):607–611. [PubMed]
  • Bradley DC, Poulin RA, Bergman RN. Dynamics of hepatic and peripheral insulin effects suggest common rate-limiting step in vivo. Diabetes. 1993 Feb;42(2):296–306. [PubMed]
  • Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes. 1987 Aug;36(8):914–924. [PubMed]
  • Molina JM, Baron AD, Edelman SV, Brechtel G, Wallace P, Olefsky JM. Use of a variable tracer infusion method to determine glucose turnover in humans. Am J Physiol. 1990 Jan;258(1 Pt 1):E16–E23. [PubMed]
  • Poulin RA, Steil GM, Moore DM, Ader M, Bergman RN. Dynamics of glucose production and uptake are more closely related to insulin in hindlimb lymph than in thoracic duct lymph. Diabetes. 1994 Feb;43(2):180–190. [PubMed]
  • Bergman RN, Bradley DC, Ader M. On insulin action in vivo: the single gateway hypothesis. Adv Exp Med Biol. 1993;334:181–198. [PubMed]
  • Zambon A, Hashimoto SI, Brunzell JD. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J Lipid Res. 1993 Jun;34(6):1021–1028. [PubMed]
  • Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem. 1993 Apr;39(4):578–582. [PubMed]
  • Cersosimo E, Judd RL, Miles JM. Insulin regulation of renal glucose metabolism in conscious dogs. J Clin Invest. 1994 Jun;93(6):2584–2589. [PMC free article] [PubMed]
  • Lewis GF, Zinman B, Groenewoud Y, Vranic M, Giacca A. Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes. 1996 Apr;45(4):454–462. [PubMed]
  • Cherrington AD, Williams PE, Shulman GI, Lacy WW. Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes. 1981 Mar;30(3):180–187. [PubMed]
  • Pagliassotti MJ, Holste LC, Moore MC, Neal DW, Cherrington AD. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. J Clin Invest. 1996 Jan 1;97(1):81–91. [PMC free article] [PubMed]
  • Cherrington AD, Liljenquist JE, Shulman GI, Williams PE, Lacy WW. Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency. Am J Physiol. 1979 Mar;236(3):E263–E271. [PubMed]
  • Carlson MG, Snead WL, Campbell PJ. Regulation of free fatty acid metabolism by glucagon. J Clin Endocrinol Metab. 1993 Jul;77(1):11–15. [PubMed]
  • Schade DS, Eaton RP. Modulation of fatty acid metabolism by glucagon in man. I. Effects in normal subjects. Diabetes. 1975 May;24(5):502–509. [PubMed]
  • Perea A, Clemente F, Martinell J, Villanueva-Peñacarrillo ML, Valverde I. Physiological effect of glucagon in human isolated adipocytes. Horm Metab Res. 1995 Aug;27(8):372–375. [PubMed]
  • Jensen MD, Heiling VJ, Miles JM. Effects of glucagon on free fatty acid metabolism in humans. J Clin Endocrinol Metab. 1991 Feb;72(2):308–315. [PubMed]
  • Jeng CY, Sheu WH, Jaspan JB, Polonsky KS, Chen YD, Reaven GM. Glucagon does not increase plasma free fatty acid and glycerol concentrations in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993 Jul;77(1):6–10. [PubMed]
  • Keller U, Miles JM. Growth hormone and lipids. Horm Res. 1991;36 (Suppl 1):36–40. [PubMed]
  • Copeland KC, Nair KS. Acute growth hormone effects on amino acid and lipid metabolism. J Clin Endocrinol Metab. 1994 May;78(5):1040–1047. [PubMed]
  • De Pergola G, Cignarelli M, Nardelli G, Garruti G, Corso M, Di Paolo S, Cardone F, Giorgino R. Influence of lactate on isoproterenol-induced lipolysis and beta-adrenoceptors distribution in human fat cells. Horm Metab Res. 1989 Apr;21(4):210–213. [PubMed]
  • Jahoor F, Klein S, Wolfe R. Mechanism of regulation of glucose production by lipolysis in humans. Am J Physiol. 1992 Mar;262(3 Pt 1):E353–E358. [PubMed]
  • Nurjhan N, Campbell PJ, Kennedy FP, Miles JM, Gerich JE. Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans. Diabetes. 1986 Dec;35(12):1326–1331. [PubMed]
  • Bortz WM, Paul P, Haff AC, Holmes WL. Glycerol turnover and oxidation in man. J Clin Invest. 1972 Jun;51(6):1537–1546. [PMC free article] [PubMed]
  • Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest. 1994 Jun;93(6):2438–2446. [PMC free article] [PubMed]
  • Nurjhan N, Consoli A, Gerich J. Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus. J Clin Invest. 1992 Jan;89(1):169–175. [PMC free article] [PubMed]
  • Fanelli C, Calderone S, Epifano L, De Vincenzo A, Modarelli F, Pampanelli S, Perriello G, De Feo P, Brunetti P, Gerich JE, et al. Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans. J Clin Invest. 1993 Oct;92(4):1617–1622. [PMC free article] [PubMed]
  • Williamson JR, Kreisberg RA, Felts PW. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci U S A. 1966 Jul;56(1):247–254. [PMC free article] [PubMed]
  • Puhakainen I, Yki-Järvinen H. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM. Diabetes. 1993 Dec;42(12):1694–1699. [PubMed]
  • Clore JN, Nestler JE, Blackard WG. Sleep-associated fall in glucose disposal and hepatic glucose output in normal humans. Putative signaling mechanism linking peripheral and hepatic events. Diabetes. 1989 Mar;38(3):285–290. [PubMed]
  • Clore JN, Glickman PS, Helm ST, Nestler JE, Blackard WG. Evidence for dual control mechanism regulating hepatic glucose output in nondiabetic men. Diabetes. 1991 Aug;40(8):1033–1040. [PubMed]
  • Chen YD, Swislocki AL, Jeng CY, Juang JH, Reaven GM. Effect of time on measurement of hepatic glucose production. J Clin Endocrinol Metab. 1988 Nov;67(5):1084–1088. [PubMed]
  • Hother-Nielsen O, Beck-Nielsen H. On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia. 1990 Oct;33(10):603–610. [PubMed]
  • Jeng CY, Sheu WH, Fuh MM, Chen YD, Reaven GM. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes. 1994 Dec;43(12):1440–1444. [PubMed]
  • Johnston P, Hollenbeck C, Sheu W, Chen YD, Reaven GM. Acute changes in plasma non-esterified fatty acid concentration do not change hepatic glucose production in people with type 2 diabetes. Diabet Med. 1990 Dec;7(10):871–875. [PubMed]
  • Fulcher GR, Walker M, Catalano C, Agius L, Alberti KG. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes. 1992 Nov;41(11):1400–1408. [PubMed]
  • Puhakainen I, Koivisto VA, Yki-Järvinen H. No reduction in total hepatic glucose output by inhibition of gluconeogenesis with ethanol in NIDDM patients. Diabetes. 1991 Oct;40(10):1319–1327. [PubMed]
  • Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA, Ferrannini E. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism. 1987 May;36(5):502–506. [PubMed]
  • Chen YD, Golay A, Swislocki AL, Reaven GM. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987 Jan;64(1):17–21. [PubMed]
  • Golay A, Chen YD, Reaven GM. Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals. J Clin Endocrinol Metab. 1986 Jun;62(6):1081–1088. [PubMed]
  • Reaven GM. The fourth musketeer--from Alexandre Dumas to Claude Bernard. Diabetologia. 1995 Jan;38(1):3–13. [PubMed]
  • Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989 Jul;84(1):205–213. [PMC free article] [PubMed]
  • Taskinen MR, Bogardus C, Kennedy A, Howard BV. Multiple disturbances of free fatty acid metabolism in noninsulin-dependent diabetes. Effect of oral hypoglycemic therapy. J Clin Invest. 1985 Aug;76(2):637–644. [PMC free article] [PubMed]
  • Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1991 Jan;72(1):96–107. [PubMed]
  • Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992 Oct;90(4):1323–1327. [PMC free article] [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...